Does weight loss increase with higher doses of semaglutide?

Step 1: why titration starts low before it can go high

Semaglutide works by activating GLP-1 receptors that regulate appetite, slow gastric emptying and reduce food intake. The therapeutic effect builds with concentration, which is why the 0.25 mg starting dose is a settling-in step, not a weight-loss target. The standard Wegovy schedule runs 0.25 mg for four weeks, then 0.5 mg, 1.0 mg, 1.7 mg and finally 2.4 mg, each rung held for roughly a month. Most gastrointestinal side effects (nausea, loose stools, indigestion) tend to peak in the first week or two after a step-up, then ease. Rushing the schedule doesn't accelerate weight loss; it mostly increases the chance of feeling rough enough to stop early. Your prescriber will only advance the dose once you've tolerated the current one and your clinical picture supports it. You can read more about how each Wegovy dose is structured and what to expect at each stage.

Step 2: what the trial data actually show at each dose level

The STEP 1 trial, published in the New England Journal of Medicine, randomised nearly 2,000 adults with obesity and followed them for 68 weeks. Those who reached and maintained the 2.4 mg dose lost an average of around 15% of their starting body weight, compared with roughly 2.4% in the placebo group. Studies at lower doses, including the 1.0 mg dose used in the diabetes medicine Ozempic, show considerably smaller weight reductions, typically in the 3–6% range. The pattern is consistent: more receptor activation, greater appetite suppression, more weight lost. There is a ceiling, though. Biology, adherence and individual variation all shape the final result, which is why whether increasing your Wegovy dose actually leads to more weight loss is a question worth understanding before assuming a step-up is always the answer. If you're weighing up semaglutide against alternatives, the evidence on higher-dose semaglutide covers the clinical picture in more depth.

Step 3: the 7.2 mg dose, what the newest approval adds

In April 2026 the MHRA approved a dedicated single-dose 7.2 mg Wegovy pen, following a January 2026 authorisation of the higher dose itself. This is the largest available dose of semaglutide for weight management in the UK, and the trial data are striking: roughly 20.7% average weight loss over 72 weeks, a figure that starts to close the gap with tirzepatide's headline results. The 7.2 mg pen has a built-in covered needle and locks after use, a practical design change that many patients will find simpler. It is licensed for adults with a BMI of 30 or above; it is not currently authorised for the lower BMI threshold or for the cardiovascular indication. The titration still begins at 0.25 mg and works up in the same four-weekly pattern, with 7.2 mg as the ceiling rather than 2.4 mg. The approved highest dose of semaglutide page covers the clinical background for the 7.2 mg approval in full. For context on how private treatment is priced across doses, the weight-loss treatment overview explains what each option involves.

What limits the dose-response, and when to raise the question with a prescriber

A higher dose isn't always the right answer. Some people lose substantial weight at 1.7 mg and experience worsening nausea at 2.4 mg, in that situation, staying at the lower dose and working on dietary habits alongside it is often the sensible call. Others plateau despite reaching 2.4 mg and tolerate it well, which is exactly the scenario the 7.2 mg pathway was designed for. The practical options for increasing weight loss on Wegovy are worth reading if you've stalled. One thing our prescribers hear regularly is the assumption that a plateau means the medicine has stopped working, usually it means the dose-response curve has been met and lifestyle factors need attention alongside it. If you ordered before noon today, your consultation is with a clinician the same day; that review is the right moment to flag a plateau, not something to sort by quietly skipping to a higher dose. The NHS semaglutide medicines page also outlines the schedule and what to do if side effects make dose increases difficult. Questions about your specific situation are best put to a prescriber directly, our FAQs cover many of the common ones.